

Italian firm to market orphan drug, Attila, in China

26 May 2014 | News | By BioSpectrum Bureau



Singapore: Italy based Abiogen Pharma is in an expansion spree in Asia and has collaborated with Hong Kong firm Lee's Pharm for license, distribution and supply of its orphan drug Attila (Neridronic Acid) throughout mainland China, Hong Kong, Macau and Taiwan.

Under the term of the agreement, Abiogen Pharma has granted Lee's Pharm an exclusive license and right for registering, importing, marketing, distributing and selling Attila for the two orphan/rare disease indications Osteogenesis Imperfecta (OI) and Complex Regional Pain Syndrome (CRPS).

Attila is registered in Italy and used by patients in 32 European countries under the trade name of Nerixia. Neridronate showed superior safety profile in long-term use and is tolerated by adults and pediatric population. It is the only bisphosphonate indicated for use in neonates and children.

Dr Massimo Di Martino, President and CEO, Abiogen Pharma said, "I am happy to see that Neridronate could cross political and geographic barriers to benefit the patients. Our partnership with Lee's Pharm will help patients in mainland China and Taiwan to fight critical rare diseases for which there is no other treatment option available."

Dr. Benjamin Li, Chief Executive Officer, Lee's Pharm said, "We're extremely pleased with our partnership with Abiogen Pharma, and excited about the opportunity to work on Neridronate in our territory. This is the fourth orphan drug we have licensed-in and it again demonstrates our commitment to rare diseases."